Get the Stockscreener App
23.89
0.50%
-0.12
Aktis Oncology Inc stock is traded at $23.89, with a volume of 193.64K.
It is down -0.50% in the last 24 hours and down -16.76% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
See More
Previous Close:
$24.01
Open:
$24.06
24h Volume:
193.64K
Relative Volume:
0.57
Market Cap:
$1.32B
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-21.23
EPS:
-1.1251
Net Cash Flow:
$-52.28M
1W Performance:
-4.02%
1M Performance:
-16.76%
6M Performance:
+10.35%
1Y Performance:
+64,120%
1-Day Range:
$23.39
$24.58
1-Week Range:
$23.39
$25.32
52-Week Range:
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Name
Aktis Oncology Inc
Sector
Industry
Phone
978-237-4380
Address
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
23.89 | 1.32B | 29.71M | -69.15M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | H.C. Wainwright | Buy |
| Feb-03-26 | Initiated | BofA Securities | Buy |
| Feb-03-26 | Initiated | JP Morgan | Overweight |
| Feb-03-26 | Initiated | Leerink Partners | Outperform |
| Feb-03-26 | Initiated | TD Cowen | Buy |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia
Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et
Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
AKTS Options Chain — NASDAQ:AKTS - TradingView
Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan
Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com - Investing.com Nigeria
Aktis Oncology, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
AKTS Options Volatility — NASDAQ:AKTS - TradingView
Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
New Options Listings Include Aktis Oncology Inc (AKTS) - GuruFocus
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 - GuruFocus
J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Price to earnings forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to EBITDA forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Aktis oncology CMO sells $1.39m in shares By Investing.com - Investing.com India
Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing - Moomoo
Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com - Investing.com Australia
Aktis oncology CMO sells $1.39m in shares - Investing.com
Form 4 Aktis Oncology Inc For: 10 July By Investing.com - Investing.com South Africa
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing - Moomoo
Aktis Oncology Insiders Sold Shares Worth Over $2.8M - TradingView
Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares - Stock Titan
Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades - Stock Titan
Form 144 AKTIS ONCOLOGY For: 8 July By Investing.com - Investing.com Nigeria
[144] Aktis Oncology, Inc. SEC Filing - Stock Titan
Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Aktis Oncology (AKTS) Gains 2.8% as Biotech Sentiment ImprovesVolume Breakout Ideas - dars.gov.et
Aktis is a strong buy at Raymond James on therapeutic platform - MSN
AKTS Q1 2026 Earnings: Results Miss Estimates as Pre-Revenue Biotech Continues Development - dars.gov.et
Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS) - TradingView
AKTS Forecast — Price Target — Prediction for 2027 - TradingView
Aktis Oncology, Inc. News — NASDAQ:AKTS - TradingView
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Global BMI Index - marketscreener.com
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage; Stock RisesEarnings Deceleration Risk - dars.gov.et
Aktis Oncology (AKTS) Gains Strong Buy Rating from Raymond James - GuruFocus
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aktis Oncology Inc Stock (AKTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Herrmann Ken | Director |
Jul 20 '26 |
Sale |
24.56 |
4,856 |
119,274 |
0 |
| Herrmann Ken | Director |
Jul 17 '26 |
Option Exercise |
0.08 |
3,065 |
245 |
3,065 |
| Herrmann Ken | Director |
Jul 17 '26 |
Sale |
25.21 |
3,065 |
77,259 |
0 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):